Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies.

Trickey A, May MT, Gill MJ, Grabar S, Vehreschild J, Wit FWNM, Bonnet F, Cavassini M, Abgrall S, Berenguer J, Wyen C, Reiss P, Grabmeier-Pfistershammer K, Guest JL, Shepherd L, Teira R, d'Arminio Monforte A, Del Amo J, Justice A, Costagliola D, Sterne JAC.

Int J Cancer. 2020 Jan 31. doi: 10.1002/ijc.32895. [Epub ahead of print]

PMID:
32003460
2.

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study.

van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla J, Routy JP, Wyen C, Ait-Khaled M, Nascimento MC, Pappa KA, Wang R, Wright J, Tenorio AR, Wynne B, Aboud M, Gartland MJ, Smith KY.

Clin Infect Dis. 2020 Jan 6. pii: ciz1243. doi: 10.1093/cid/ciz1243. [Epub ahead of print]

PMID:
31905383
3.

Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings.

Trickey A, van Sighem A, Stover J, Abgrall S, Grabar S, Bonnet F, Berenguer J, Wyen C, Casabona J, d'Arminio Monforte A, Cavassini M, Del Amo J, Zangerle R, Gill MJ, Obel N, Sterne JAC, May MT.

AIDS. 2019 Dec 15;33 Suppl 3:S271-S281. doi: 10.1097/QAD.0000000000002387.

4.

Parameter estimates for trends and patterns of excess mortality among persons on ART in high-income european settings.

Trickey A, van Sighem A, Stover J, Abgrall S, Grabar S, Bonnet F, Berenguer J, Wyen C, Casabona J, Monforte AD'A, Cavassini M, Del Amo J, Zangerle R, Gill MJ, Obel N, Sterne JAC, May MT.

AIDS. 2019 Nov 19. doi: 10.1097/QAD.0000000000002387. [Epub ahead of print]

PMID:
31764067
5.

Systematic Review and Meta-analysis of Treatment Interruptions in Human Immunodeficiency Virus (HIV) Type 1-infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials.

Stecher M, Claßen A, Klein F, Lehmann C, Gruell H, Platten M, Wyen C, Behrens G, Fätkenheuer G, Vehreschild JJ.

Clin Infect Dis. 2020 Mar 17;70(7):1406-1417. doi: 10.1093/cid/ciz417.

PMID:
31102444
6.

Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party.

Hübel K, Re A, Boumendil A, Finel H, Hentrich M, Robinson S, Wyen C, Michieli M, Kanfer E, Diez-Martin JL, Balsalobre P, Vincent L, Schroyens W, Santasusana JMR, Kröger N, Schiel X, Cwynarski K, Esquirol A, Sousa AB, Cattaneo C, Montoto S, Dreger P.

Bone Marrow Transplant. 2019 Oct;54(10):1625-1631. doi: 10.1038/s41409-019-0480-x. Epub 2019 Feb 25.

PMID:
30804486
7.

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.

Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Karagounis T, Cohen YZ, Wyen C, Scholten S, Handl L, Belblidia S, Dizon JP, Vehreschild JJ, Witmer-Pack M, Shimeliovich I, Jain K, Fiddike K, Seaton KE, Yates NL, Horowitz J, Gulick RM, Pfeifer N, Tomaras GD, Seaman MS, Fätkenheuer G, Caskey M, Klein F, Nussenzweig MC.

Nat Med. 2018 Nov;24(11):1701-1707. doi: 10.1038/s41591-018-0186-4. Epub 2018 Sep 26.

8.

Combination therapy with anti-HIV-1 antibodies maintains viral suppression.

Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Lorenzi JCC, Cohen YZ, Wyen C, Kümmerle T, Karagounis T, Lu CL, Handl L, Unson-O'Brien C, Patel R, Ruping C, Schlotz M, Witmer-Pack M, Shimeliovich I, Kremer G, Thomas E, Seaton KE, Horowitz J, West AP Jr, Bjorkman PJ, Tomaras GD, Gulick RM, Pfeifer N, Fätkenheuer G, Seaman MS, Klein F, Caskey M, Nussenzweig MC.

Nature. 2018 Sep;561(7724):479-484. doi: 10.1038/s41586-018-0531-2. Epub 2018 Sep 26.

9.

To prescribe, or not to prescribe: decision making in HIV-1 post-exposure prophylaxis.

Scholten M, Suárez I, Platten M, Kümmerle T, Jung N, Wyen C, Ernst A, Horn C, Burst V, Suárez V, Rybniker J, Fätkenheuer G, Lehmann C.

HIV Med. 2018 Oct;19(9):645-653. doi: 10.1111/hiv.12645. Epub 2018 Jul 11.

PMID:
29993176
10.

Malignant lymphoma in the HIV-positive patient.

Meister A, Hentrich M, Wyen C, Hübel K.

Eur J Haematol. 2018 Jul;101(1):119-126. doi: 10.1111/ejh.13082. Epub 2018 May 22. Review.

PMID:
29663523
11.

Prevalence of asymptomatic sexually transmitted infections in HIV-positive men who have sex with men in Germany: results of a multicentre cross-sectional study.

Spinner CD, Boesecke C, Jordan C, Wyen C, Kümmerle T, Knecht G, Scholten S, Zink A, Krznaric I, Noe S.

Infection. 2018 Jun;46(3):341-347. doi: 10.1007/s15010-018-1124-6. Epub 2018 Feb 19.

PMID:
29460228
12.

Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study.

Schommers P, Gillor D, Hentrich M, Wyen C, Wolf T, Oette M, Zoufaly A, Wasmuth JC, Bogner JR, Müller M, Esser S, Schleicher A, Jensen B, Stoehr A, Behrens G, Schultze A, Siehl J, Thoden J, Taylor N, Hoffmann C.

Haematologica. 2018 May;103(5):857-864. doi: 10.3324/haematol.2017.180893. Epub 2018 Feb 8.

13.

Reply to Letter 'Morning dosing for dolutegravir-related insomnia and sleep disorders' by Capetti et al.

Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C.

HIV Med. 2018 May;19(5):e60-e61. doi: 10.1111/hiv.12539. Epub 2017 Aug 29. No abstract available.

PMID:
28851009
14.

Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients.

Welz T, Wyen C, Hensel M.

Oncol Res Treat. 2017;40(3):120-127. doi: 10.1159/000458443. Epub 2017 Feb 24. Review.

PMID:
28253501
15.

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.

Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY, Learn GH, Cohen YZ, Lehmann C, Gillor D, Shimeliovich I, Unson-O'Brien C, Weiland D, Robles A, Kümmerle T, Wyen C, Levin R, Witmer-Pack M, Eren K, Ignacio C, Kiss S, West AP Jr, Mouquet H, Zingman BS, Gulick RM, Keler T, Bjorkman PJ, Seaman MS, Hahn BH, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC, Klein F.

Nat Med. 2017 Feb;23(2):185-191. doi: 10.1038/nm.4268. Epub 2017 Jan 16.

16.

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.

Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C.

HIV Med. 2017 Jan;18(1):56-63. doi: 10.1111/hiv.12468. Epub 2016 Nov 10.

17.

CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma.

Hoffmann C, Schommers P, Wolf E, Müller M, Schultze A, Krznaric I, Stoehr A, Wolf T, Fäktenheuer G, Stier B, Wyen C, Hentrich M.

AIDS. 2016 Mar 13;30(5):753-60. doi: 10.1097/QAD.0000000000000980.

PMID:
26605513
18.

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.

Cummins NW, Neuhaus J, Chu H, Neaton J, Wyen C, Rockstroh JK, Skiest DJ, Boyd MA, Khoo S, Rotger M, Telenti A, Weinshilboum R, Badley AD; INSIGHT Study Group.

EBioMedicine. 2015 May 12;2(7):706-12. doi: 10.1016/j.ebiom.2015.05.012. eCollection 2015 Jul.

19.

Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.

Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Little RF, Dunleavy K, Wilson WH, Wyen C, Remick SC, Kaplan LD, Ratner L, Noy A, Sparano JA.

Ann Oncol. 2015 May;26(5):958-66. doi: 10.1093/annonc/mdv036. Epub 2015 Jan 28. Review.

20.

Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort.

Schommers P, Hentrich M, Hoffmann C, Gillor D, Zoufaly A, Jensen B, Bogner JR, Thoden J, Wasmuth JC, Wolf T, Oette M, Müller M, Esser S, Vehreschild JJ, Fätkenheuer G, Wyen C.

Br J Haematol. 2015 Mar;168(6):806-10. doi: 10.1111/bjh.13221. Epub 2014 Nov 17.

PMID:
25403997
21.

Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study.

Hoffmann C, Hentrich M, Gillor D, Behrens G, Jensen B, Stoehr A, Esser S, van Lunzen J, Krznaric I, Müller M, Oette M, Hensel M, Thoden J, Fätkenheuer G, Wyen C.

HIV Med. 2015 Apr;16(4):261-4. doi: 10.1111/hiv.12200. Epub 2014 Sep 23.

22.

A new prognostic score for AIDS-related lymphomas in the rituximab-era.

Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano JA.

Haematologica. 2014 Nov;99(11):1731-7. doi: 10.3324/haematol.2014.111112. Epub 2014 Aug 22.

23.

Atazanavir exposure is effective during pregnancy regardless of tenofovir use.

Colbers A, Hawkins D, Hidalgo-Tenorio C, van der Ende M, Gingelmaier A, Weizsäcker K, Kabeya K, Taylor G, Rockstroh J, Lambert J, Moltó J, Wyen C, Sadiq ST, Ivanovic J, Giaquinto C, Burger D; PANNA network.

Antivir Ther. 2015;20(1):57-64. doi: 10.3851/IMP2820. Epub 2014 Jul 3.

PMID:
24992294
24.

Clinical course and quality of care in ART-naïve patients newly presenting in a HIV outpatient clinic.

Platten M, Linnemann R, Kümmerle T, Jung N, Wyen C, Ehren K, Gravemann S, Gillor D, Cornely OA, Fischer J, Lehmann C, Rockstroh JK, Fätkenheuer G, Vehreschild JJ.

Infection. 2014 Oct;42(5):849-57. doi: 10.1007/s15010-014-0646-9. Epub 2014 Jun 26.

PMID:
24965613
25.

Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG).

Hentrich M, Hoffmann C, Mosthaf F, Müller M, Siehl J, Wyen C, Hensel M; German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ); German AIDS Society (DAIG).

Ann Hematol. 2014 Jun;93(6):913-21. doi: 10.1007/s00277-014-2058-4. Epub 2014 Mar 29. Erratum in: Ann Hematol. 2014 Aug;93(8):1445.

PMID:
24807241
26.

Echocardiographic screening for pulmonary arterial hypertension in HIV-positive patients.

ten Freyhaus H, Vogel D, Lehmann C, Kümmerle T, Wyen C, Fätkenheuer G, Rosenkranz S.

Infection. 2014 Aug;42(4):737-41. doi: 10.1007/s15010-014-0610-8. Epub 2014 Mar 12.

PMID:
24619834
27.

Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.

Xicoy B, Ribera JM, Müller M, García O, Hoffmann C, Oriol A, Hentrich M, Grande C, Wasmuth JC, Esteve J, van Lunzen J, Del Potro E, Knechten H, Brunet S, Mayr C, Escoda L, Schommers P, Alonso N, Vall-Llovera F, Pérez M, Morgades M, González J, Fernández A, Thoden J, Gökbuget N, Hoelzer D, Fätkenheuer G, Wyen C; PETHEMA Group and German HIV Lymphoma Cohort.

Leuk Lymphoma. 2014 Oct;55(10):2341-8. doi: 10.3109/10428194.2013.878933. Epub 2014 Feb 25.

PMID:
24397614
28.

Causes of death in HIV-infected patients from the Cologne-Bonn cohort.

Ehren K, Hertenstein C, Kümmerle T, Vehreschild JJ, Fischer J, Gillor D, Wyen C, Lehmann C, Cornely OA, Jung N, Gravemann S, Platten M, Wasmuth JC, Rockstroh JK, Boesecke C, Schwarze-Zander C, Fätkenheuer G.

Infection. 2014 Feb;42(1):135-40. doi: 10.1007/s15010-013-0535-7. Epub 2013 Oct 1.

PMID:
24081925
29.

Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).

Thoden J, Potthoff A, Bogner JR, Brockmeyer NH, Esser S, Grabmeier-Pfistershammer K, Haas B, Hahn K, Härter G, Hartmann M, Herzmann C, Hutterer J, Jordan AR, Lange C, Mauss S, Meyer-Olson D, Mosthaf F, Oette M, Reuter S, Rieger A, Rosenkranz T, Ruhnke M, Schaaf B, Schwarze S, Stellbrink HJ, Stocker H, Stoehr A, Stoll M, Träder C, Vogel M, Wagner D, Wyen C, Hoffmann C; Deutsche AIDS Gesellschaft; Österreichische AIDS-Gesellschaft.

Infection. 2013 Sep;41 Suppl 2:S91-115. doi: 10.1007/s15010-013-0504-1. Epub 2013 Sep 14.

30.

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.

Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Oriol A, Navarro JT, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA.

Blood. 2013 Nov 7;122(19):3251-62. doi: 10.1182/blood-2013-04-498964. Epub 2013 Sep 6. Review.

31.

Evaluation of an infectious disease consultation programme in a German tertiary care hospital.

Vehreschild JJ, Morgen G, Cornely OA, Hartmann P, Koch S, Kalka-Moll W, Wyen C, Vehreschild MJ, Lehmann C, Gillor D, Seifert H, Kremer G, Fätkenheuer G, Jung N.

Infection. 2013 Dec;41(6):1121-8. doi: 10.1007/s15010-013-0512-1. Epub 2013 Aug 8.

PMID:
23925637
32.

HIV-associated lung cancer: survival in an unselected cohort.

Hoffmann C, Kohrs F, Sabranski M, Wolf E, Jaeger H, Wyen C, Siehl J, Baumgarten A, Hensel M, Jessen A, Schaaf B, Vogel M, Bogner J, Horst HA, Stephan C.

Scand J Infect Dis. 2013 Oct;45(10):766-72. doi: 10.3109/00365548.2013.810813. Epub 2013 Jul 23.

PMID:
23876190
33.

Short-course antiretroviral therapy in primary HIV infection.

Lehmann C, Wyen C, Fätkenheuer G.

N Engl J Med. 2013 May 23;368(21):2036. doi: 10.1056/NEJMc1303486. No abstract available.

PMID:
23697519
34.

Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study.

Schommers P, Wyen C, Hentrich M, Gillor D, Zoufaly A, Jensen B, Bogner JR, Thoden J, Wasmuth JC, Fätkenheuer G, Hoffmann C.

AIDS. 2013 Mar 13;27(5):842-5. doi: 10.1097/QAD.0b013e32835e069d.

PMID:
23574794
35.

The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.

Colbers AP, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, Weizsäcker K, Sadiq ST, Ivanovic J, Giaquinto C, Taylor GP, Moltó J, Burger DM; PANNA network.

AIDS. 2013 Mar 13;27(5):739-48. doi: 10.1097/QAD.0b013e32835c208b.

PMID:
23169329
36.

Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.

Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C.

J Clin Oncol. 2012 Nov 20;30(33):4117-23. doi: 10.1200/JCO.2012.41.8137. Epub 2012 Oct 8. Erratum in: J Clin Oncol. 2012 Dec 20;30(36):4590.

PMID:
23045592
37.

No evidence for an early excess incidence of progressive multifocal leukencephalopathy in HIV-infected patients treated with rituximab.

Hoffmann C, Gérard L, Wyen C, Oksenhendler E.

J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):e121-2. doi: 10.1097/QAI.0b013e31825e2a48. No abstract available.

PMID:
22820725
38.

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.

Siccardi M, Almond L, Schipani A, Csajka C, Marzolini C, Wyen C, Brockmeyer NH, Boffito M, Owen A, Back D.

Clin Pharmacol Ther. 2012 Oct;92(4):494-502. doi: 10.1038/clpt.2012.61. Epub 2012 Jul 18.

PMID:
22805423
39.

Liver involvement in HIV-infected patients diagnosed with syphilis.

Jung N, Kümmerle T, Brengelmann SD, Gielen J, Lehmann C, Wyen C, Birtel A, Fischer J, Gillor D, Koch S, Vehreschild JJ, Cornely OA, Fätkenheuer G.

Infection. 2012 Oct;40(5):543-7. doi: 10.1007/s15010-012-0264-3. Epub 2012 Apr 25.

PMID:
22531883
40.

Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.

Wyen C, Jensen B, Hentrich M, Siehl J, Sabranski M, Esser S, Gillor D, Müller M, Van Lunzen J, Wolf T, Bogner JR, Wasmuth JC, Christ H, Fätkenheuer G, Hoffmann C.

AIDS. 2012 Feb 20;26(4):457-64. doi: 10.1097/QAD.0b013e32834f30fa.

PMID:
22112600
41.

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.

Liptrott NJ, Pushpakom S, Wyen C, Fätkenheuer G, Hoffmann C, Mauss S, Knechten H, Brockmeyer NH, Hopper-Borge E, Siccardi M, Back DJ, Khoo SH, Pirmohamed M, Owen A; German Competence Network for HIV/AIDS.

Pharmacogenet Genomics. 2012 Jan;22(1):10-9. doi: 10.1097/FPC.0b013e32834dd82e.

42.

Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.

Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS; AIDS Clinical Trial Group DACS 241 Team; AIDS Clinical Trial Group Study 5095 Team; AIDS Clinical Trial Group Study 5142 team; Antiretroviral Cohort Collaboration.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):253-60. doi: 10.1097/QAI.0b013e318230372e.

43.

Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne-Bonn cohort.

Steffens B, Kümmerle T, Koch S, Birtel A, Schwarze-Zander C, Emmelkamp J, Kern WV, Hertenstein C, Wyen C, Lehmann C, Cornely OA, Rockstroh J, Fätkenheuer G.

Eur J Med Res. 2011 Jul 25;16(7):289-94.

44.

Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease.

Hoffmann C, Schmid H, Müller M, Teutsch C, van Lunzen J, Esser S, Wolf T, Wyen C, Sabranski M, Horst HA, Reuter S, Vogel M, Jäger H, Bogner J, Arasteh K.

Blood. 2011 Sep 29;118(13):3499-503. doi: 10.1182/blood-2011-02-333633. Epub 2011 Jul 21.

PMID:
21778341
45.

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS Coordinators.

J Antimicrob Chemother. 2011 Sep;66(9):2092-8. doi: 10.1093/jac/dkr272. Epub 2011 Jun 29.

46.

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.

Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, Fätkenheuer G, Youle M, Rockstroh J, Brockmeyer NH, Johnson MA, Owen A, Back DJ; German Competence Network for HIV/AIDS.

J Antimicrob Chemother. 2011 Jun;66(6):1332-9. doi: 10.1093/jac/dkr087. Epub 2011 Mar 25.

47.

Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?

Jetter A, Fätkenheuer G, Frank D, Klaassen T, Seeringer A, Doroshyenko O, Kirchheiner J, Hein W, Schömig E, Fuhr U, Wyen C.

Antivir Ther. 2010;15(7):975-83. doi: 10.3851/IMP1648.

48.

Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.

Janneh O, Bray PG, Jones E, Wyen C, Chiba P, Back DJ, Khoo SH.

J Antimicrob Chemother. 2010 May;65(5):906-16. doi: 10.1093/jac/dkq082. Epub 2010 Mar 17.

49.

Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection.

Kümmerle T, Lehmann C, Hartmann P, Wyen C, Fätkenheuer G.

Expert Opin Investig Drugs. 2009 Nov;18(11):1773-85. doi: 10.1517/13543780903357478.

PMID:
19888873
50.

The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.

van der Lugt J, Colbers A, Molto J, Hawkins D, van der Ende M, Vogel M, Wyen C, Schutz M, Koopmans P, Ruxrungtham K, Richter C, Burger D; SARA study team.

Antivir Ther. 2009;14(3):443-50.

PMID:
19474478

Supplemental Content

Support Center